Neuroendocrinology | Medical XPRT
Articles & Whitepapers
-
Protein Fusion Extends Drug Half-Life Technology
Protein fusion is a genetic recombination technique in which the DNA of an inactive peptide or protein chain segment to be grafted is recombined with the DNA of a drug and expressed together by engineered cells; no specialized grafting operations are required. In the current technology, the inactive peptide or protein chain segment used for protein fusion is the FC region of albumin and antibody. ...
-
Application of Capillary Electrophoresis Technology in Biopharmaceuticals
Capillary Electrophoresis (CE) is an analytical technique used in the development and quality control of protein drugs. From medium optimization, clone screening, formulation stability research and ...
News
-
Lumos Pharma to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will present at the H.C. Wainwright Virtual BIOCONNECT Conference being held January 10-13, 2022. A ...
Pronalyse’s Fusion Protein Characterization Service Aids in the Drug Development Process
Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD
Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare Conference
Juvena Therapeutics Secures $41 Million to Accelerate the Discovery and Development of Biologics for Chronic and Age-Related Diseases
Equipment & Solutions
-
Showcase
Adrenocorticotrophic Hormone-ACTH
Species: Mouse,Immunogen: Synthetic peptide corresponding to aa 1-24 of human ACTH, Clone: AH26, Isotype: IgG1, kappa, Species Reactivity: Human, Mouse and Rat. Expected to show a broad species reactivity. Positive Control: Normal pituitary gland or pituitary tumor. Specificity: This antibody is specific to Synacthen (aa 1-24 of ACTH); this antibody does not react with CLIP (aa 17-39 of ACTH). ...